导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | -4.53% | 3265/4773 |
| 近一周 | -1.87% | 809/5462 |
| 近一月 | -2.00% | 1122/5421 |
| 近一季 | -1.94% | 1106/5209 |
| 近半年 | -2.37% | 1877/4920 |
| 近一年 | -1.93% | 2944/4366 |
| 近两年 | 32.89% | 2163/2954 |
| 近三年 | 19.94% | 1469/2253 |
| 成立以来 | 14.19% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-6.38% 4118/4961 |
5.97% 2862/5312 |
- - |
- - |
| 2025 | 15.44% 2543/4813 |
-0.42% 2235/3635 |
2.84% 1317/4076 |
10.74% 3247/4524 |
1.79% 1217/4813 |
| 2024 | 17.02% 737/3463 |
3.40% 577/2808 |
-0.35% 743/3014 |
16.45% 1454/3129 |
-2.47% 2099/3463 |
| 2023 | -8.94% 1076/2656 |
0.72% 1710/2280 |
-4.64% 1232/2385 |
1.64% 295/2515 |
-6.72% 1896/2655 |
| 2022 | -16.92% 532/2207 |
-11.08% 478/1919 |
6.41% 705/2016 |
-13.25% 866/2113 |
1.21% 1346/2208 |
| 2021 | -8.95% 1064/1822 |
-3.04% 748/1255 |
-0.24% 1132/1330 |
-7.65% 1072/1466 |
1.93% 749/1822 |
| 2020 | 20.11% 723/1250 |
-11.58% 843/1028 |
10.13% 775/1067 |
10.39% 558/1164 |
11.73% 522/1184 |
| 2019 | 31.61% 462/1092 |
21.79% 592/754 |
3.00% 64/804 |
-0.10% 577/850 |
5.03% 758/918 |
| 2018 | -17.29% 127/834 |
- - |
- - |
- - |
-11.58% 320/691 |
| 2017 | 25.98% 107/714 |
- - |
- - |
- - |
- - |
| 2016 | -2.43% 131/605 |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 天弘恒生沪深港创新药精选50ETF | 0.8428 | 28.18% |
| 港股通药 | 0.8930 | 27.53% |
| 天弘恒生沪深港创新药精选50ETF发起联接A | 1.2971 | 26.78% |
| 华富中证港股通创新药指数型发起式C | 1.1445 | 26.30% |
| 万家中证港股通创新药ETF | 1.5973 | 26.27% |
| 景顺长城中证港股通创新药ETF | 1.6587 | 26.20% |
| 天弘恒生沪深港创新药精选50ETF发起联接C | 1.2831 | 25.87% |
| 港医疗 | 0.8885 | 25.59% |
| 景顺长城中证港股通创新药ETF联接A | 1.4594 | 25.50% |
| 华富中证港股通创新药指数型发起式A | 1.1526 | 25.42% |
| 华夏上证50ETF联接A VS. 长安沪深300非周期A(740101) |